Tropical Journal of Pharmaceutical Research March 2016; 15 (3): 577-581

ISSN: 1596-5996 (print); 1596-9827 (electronic)

© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved.

> Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v15i3.20

Original Research Article

Inhibition of Caspase-3, -6, -8 and -9 Expression in Rats with Acute Spinal Cord Injury by Cantharidin Treatment

Gang Zhao¹, Xiao-Hui Wang¹*, Ren-Qian Song¹ and Chun-Lin Zhang²

¹Department of Spine Surgery, Luoyang Orthopedic-Traumatological Hospital, Luoyang Henan 471002, ²Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, 450000, China

*For correspondence: Email: wangxiaohuiw@hotmail.com; Tel/Fax: 0086-317-666666

Received: 1 July 2015 Revised accepted: 6 February 2016

Abstract

Purpose: To demonstrate the anti-apoptotic effects of cantharidin in mice with acute spinal cord injury (ASCI).

Methods: In total, 30 male Sprague-Dawley mice were divided into three groups of 10 animals each. ASCI was induced in two of the groups using a modified Allen's method, consisting of treatment with 10 mg/kg body weight cantharidin after injury, and sacrifice on days 2, 5, 10, 20 and 30 to extract the spinal cord. The activity levels of caspase-3, -6, -8, and -9 were determined spectrophotometrically at 455 nm with a microplate reader.

Results: The results showed that cantharidin treatment caused a significant reduction in the expression levels of all four caspases - caspase-3, -6, -8, and -9 - compared with the untreated groups. Two hours after ASCI, caspase levels in the cantharidin-treated group increased, reaching maximum after day 5, but were significantly lower than in the untreated group. The expression levels of caspases in the cantharidin-treated group were similar to those in the control group on days 20 and 30 following ASCI (p > 0.05).

Conclusion: Cantharidin treatment exerts an anti-apoptotic effect against secondary spinal cord injury (SCI) by suppressing caspase activity. Thus, cantharidin may be suitable for the treatment of secondary

Keywords: Cantharidin, Caspase, Anti-apoptotic, Inhibition, Regeneration

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

Spinal cord injury (SCI) characterised by a break in the spinal cord is among the most severe health problems worldwide and is caused mainly by traffic accidents [1,2]. Two phases of SCI have been defined: the acute phase, resulting from compression and haemorrhage of tissues. and the secondary phase, which is accompanied by cell apoptosis at the lesion [1,2]. The secondary injury phase is usually more problematic and severe than the primary injury phase, leading to long-lasting disability. Because

nervous system tissues do not possess the ability to regenerate, treatment should be free from side effects, and should be administered systemically [3]. Early treatment of acute spinal cord injury (ACSI) involves protection of the uninjured spinal cord, prevention of secondary injury, and promotion of spinal cord function. Many molecules have been used to inhibit the process of cell apoptosis in neurological disorders, such as traumatic brain injury [3,4]. The inhibition of apoptosis in the spinal cord has been reported to play an important role after ASCI [5]. For the inhibition of apoptosis,

suppression of caspase activation by chemotherapeutic agents can be highly effective.

Cantharidin, a terpenoid isolated from the blister beetle, a member of the Meloidae family and Coleoptera order [6], has been used in traditional Chinese medicine for the treatment of various disorders [7]. Cantharidin treatment had been shown to induce cell cycle arrest in cancer cells [8]. In addition, cantharidin treatment induces apoptosis in different types of cancer cell, including hepatoma [9], colon [10], bladder [11], [12], and leukaemia Furthermore, in T24 cells, treatment with cantharidin has been shown to induce overexpression of COX2 and production of PGE2 [11].

In the present study, the effect of cantharidin on the spinal cord after ASCI was studied in mice. The results demonstrated that cantharidin treatment inhibited the expression of caspase-3, -6, -8, and -9. These caspases are known to play an important role in the process of cell apoptosis.

EXPERIMENTAL

Chemicals and reagents

Cantharidin and dimethyl sulphoxide were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Penicillin injections were purchased from Gibco BRL (Grand Island, NY, USA).

Animals

Adult male Sprague-Dawley mice (~190-210 g) were obtained from the Shanghai Laboratory Animal Commission (Shanghai, China). All procedures experimental were performed according to the Guidance for the Care and Use of Laboratory Animals (2012) of the Ministry of Science and Technology of the People's Republic of China, and ethical approval was granted by the institutional ethical committee. The animals were acclimatised to the laboratory conditions 1 week before the experiment was started and were housed in a room with 12-h dark/light cycle.

Preparation of the ASCI animal model and treatment strategy

In total, 30 animals were divided randomly into three groups of 10 animals each: (a) a control group without SCI, (b) a group of animals with SCI that received no treatment, and a group of animals with SCI treated with cantharidin. Cantharidin was administered to each animal at a concentration of 10 mg/kg body weight after

injury. Animals in control and untreated groups received an equal volume of normal saline.

Sample collection

The animals were sacrificed on days 2, 5, 10, 20, and 30 after injury to extract the spinal cord. For the purpose of spinal cord extraction, a small incision was made on the dorsal side after the animal was anaesthetised, followed by removal of skin and other subcutaneous tissues. After exposure, the spinal cord was removed carefully and placed in lysis buffer (40 mmol/l Tris HCl, 1 mmol/l EDTA, 150 mmol/l KCl, 100 mmol/L NaVO₃, 1 % Triton X 100, and 1 mmol/L PMSF; pH 7.5) for homogenation.

The homogenised tissues were put into tubes (1.5 mL) and centrifuged for 45 min at 12,000 rpm. Following centrifugation, the solid material was removed and put into the centrifuge tube. The tubes were then stored at -80 °C for determination of caspase levels.

ELISA for determination of caspase activity

An enzyme-linked immunosorbent assay (ELISA) kit (DVE00; R&D Systems, Minneapolis, MN, USA) was used for the determination of caspase activity according to the manufacturer's protocol. Briefly, dilution solutions were prepared with 1.8 mL detection buffer and 0.2 mL lysis buffer. Dilution combinations - 0, 10, 20, 50, 100, and 200 μM 4-nitroaniline – were prepared and used as controls.

Absorbance at 455 nm was recorded for 100-µL samples. The absorbance values for blank wells were subtracted from those of the standard samples (Chemicon, Temecula, CA, USA) with respect to caspase-3 activity. Similarly, absorbance was recorded for the caspases.

Western blotting for apoptosis-associated proteins

The spinal cord tissues were lysed in lysis buffer containing 40 mM Tris-HCl (pH 7.4), 10 mM EDTA, 120 mM NaCl, 1 mM dithiothreitol, and 0.1 % Nonide P-40. Total proteins were separated on 10 % Tris-glycine SDS-polyacrylamide gels and then transferred to a nitrocellulose membrane by electroblotting. The membranes were incubated with primary antibodies for caspase-3, -6, -8, and 9 (R&D Systems).

After incubation, the membranes were washed with PBS, followed by incubation with secondary antibodies for enhanced chemiluminescence

(NEN Life Science Products, Inc., Boston, MA, USA). The anti-ß-tubulin from a mouse monoclonal antibody was used as the loading control.

Statistical analysis

SPSS for Windows software package (ver. 18.0; SPSS Inc., Chicago, IL, USA) was used for statistical analysis of the data obtained. The data are presented as mean \pm standard error of the mean (SEM). For comparison of means among groups, one way analysis of variance and posthoc least significant difference test were used. Differences were considered statistically significant at p < 0.05.

RESULTS

Using ELISA and western blot analyses in the control group, the activity of caspase-3, -6, and -8 was determined to remain similar throughout the treatment period.

Examination of the expression of caspase-3, -6, -8, and -9, using ELISA and western blot analyses in the treatment group revealed that administration of cantharidin caused a marked reduction in the expression of caspases compared with the untreated rats on days 2, 5, 10, and 20. However, on day 30, the expression levels of caspases in the treated and untreated ACSI groups were similar and close to those of the control group (Tables 1-4, Fig 1).

Table 1: Caspase-3 activity in untreated and treatment groups

| Day | Group | Activity (mean ± SD) | t | <i>P</i> -value |
|-----|-----------|------------------------|--------|-----------------|
| 2 | Control | 19.32459 ± 0.45678 | 3.512 | 0.028 |
| | Treatment | 18.54321 ± 0.54367 | | |
| 5 | Control | 40.76435 ± 1.02314 | 27.723 | 0.000 |
| | Treatment | 23.65987 ± 0.75432 | | |
| 10 | Control | 27.78450 ± 0.32314 | 22.754 | 0.000 |
| | Treatment | 17.21132 ± 0.26342 | | |
| 20 | Control | 5.43562 ± 0.07474 | 2.126 | 0.093 |
| | Treatment | 3.97965 ± 0.06783 | | |
| 30 | Control | 2.87967 ± 0.09123 | 0.354 | 0.834 |
| | Treatment | 2.45672 ± 0.00354 | | |

Table 2: Caspase-6 activity in control and treatment groups

| Day | Group | Activity (mean ± SD) | t | <i>P</i> -value |
|-----|-----------|------------------------|--------|-----------------|
| 2 | Control | 0.02564 ± 0.00321 | 3.178 | 0.011 |
| | Treatment | 0.00341 ± 0.00021 | | |
| 5 | Control | 0.78654 ± 0.06578 | 19.871 | 0.000 |
| | Treatment | 0.5789 ± 0.02116 | | |
| 10 | Control | 0.69411 ± 0.07543 | 17.437 | 0.000 |
| | Treatment | 0.42143 ± 0.06347 | | |
| 20 | Control | 0.34517 ± 0.03452 | 3.732 | 0.047 |
| | Treatment | 0.231913 ± 0.02341 | | |
| 30 | Control | 0.02354 ± 0.00165 | 0.124 | 0.795 |
| | Treatment | 0.02160 ± 0.00134 | | |

Table 3: Caspase-8 activity in control and treatment groups

| Day | Group | Activity (mean ± SD) | t | P-value |
|-----|-----------|------------------------|--------|---------|
| 2 | Control | 18.34234 ± 1.22314 | 3.034 | 0.044 |
| | Treatment | 17.78421 ± 1.00341 | | |
| 5 | Control | 29.53262 ± 1.96532 | 27.674 | 0.000 |
| | Treatment | 21.68453 ± 1.21152 | | |
| 10 | Control | 23.46535 ± 1.00545 | 21.974 | 0.000 |
| | Treatment | 13.45537 ± 0.87054 | | |
| 20 | Control | 6.77682 ± 0.62132 | 2.354 | 0.098 |
| | Treatment | 5.00413 ± 0.25643 | | |
| 30 | Control | 3.57324 ± 0.09786 | 0.214 | 0.893 |
| | Treatment | 2.66753 ± 0.06553 | | |

Table 4: Caspase-9 activity in untreated and treatment groups

| Group | Activity (mean ± SD) | t | <i>P</i> -value |
|-----------|---|---|---|
| Control | 9.75972 ± 0.57823 | 3.017 | 0.017 |
| Treatment | 8.97634 ± 0.52734 | | |
| Control | 15.63115 ± 0.95211 | 17.754 | 0.000 |
| Treatment | 9.43263 ± 0.65247 | | |
| Control | 5.82533 ± 0.26399 | 16.135 | 0.000 |
| Treatment | 3.59882 ± 0.171266 | | |
| Control | 1.24541 ± 0.07342 | 6.561 | 0.053 |
| Treatment | 0.86734 ± 0.05776 | | |
| Control | 0.35643 ± 0.01547 | 0.214 | 0.896 |
| Treatment | 0.15412 ± 0.00487 | | |
| | Control Treatment Control Treatment Control Treatment Control Treatment Control Treatment Control | $ \begin{array}{llllllllllllllllllllllllllllllllllll$ | Control 9.75972 ± 0.57823 3.017 Treatment 8.97634 ± 0.52734 17.754 Control 15.63115 ± 0.95211 17.754 Treatment 9.43263 ± 0.65247 16.135 Control 5.82533 ± 0.26399 16.135 Treatment 3.59882 ± 0.171266 6.561 Control 1.24541 ± 0.07342 6.561 Treatment 0.86734 ± 0.05776 0.214 Control 0.35643 ± 0.01547 0.214 |




Figure 2: Western blot analysis showing reduction in the expression levels of caspase-3, -6, -8, and -9 in mice on days 2, 5, 10, 20, and 30 after treatment with cantharidin for spinal injury. The expression of caspases was inhibited significantly in the cantharidin-treated group compared with the untreated group

DISCUSSION

Cantharidin, which has been used in traditional Chinese medicine, induces arrest of the cell cycle in cancer cells [7,8]. In addition, cantharidin treatment of different types of cancer cell, including hepatoma [9], colon [10], bladder [11], breast [12], oral buccal and leukaemia [13] cells, has been shown to induce apoptosis. The present study was performed to investigate the effect of cantharidin on apoptosis in the spinal

cord after injury in rats. The results demonstrated that cantharidin treatment inhibited the expression of caspase-3, -6, -8, and -9, which together represent the vital proteases involved in the process of cell apoptosis.

Cellular apoptosis plays an important role in the human body by removing unwanted cells; however, in patients with SCI, it leads to the development of secondary injury. Apoptosis is initiated and regulated by various factors, including caspases, Bcl 2, and Bax [14–16].

Studies have shown that increased expression of caspases results in the induction of apoptosis [17]. Among the various known caspases, initiator caspases (caspase-2, -8, -9, and -10) begin the apoptotic process. Caspase 3 has also been reported to be the most important initiator caspase, and to play a vital role in initiating apoptosis. The expression of caspase-3 induces various proteins, such as PAK2, mdm2, D4-GDI, and PARP, which in turn induce cell apoptosis. The data from the present study demonstrate that the expression of initiator (caspase-8 and -9) and effector (caspase-3 and -6) caspases was reduced in rats treated with cantharidin on days 2, 5, 10, and 20.

Previous studies have shown that caspase-3 activation in turn activates caspase-8 through a sequence of changes [18]. However, the results from our study revealed that cantharidin treatment inhibited the expression of caspase-8, which may have been due to a reduction in the expression of caspase-6.

Caspase-9, another member of the initiator caspase family, is involved in inducing apoptosis through the mitochondria. Our results showed that administration of cantharidin also reduced the expression of caspase-9; these results were verified by western blot analysis. These findings support the ability of cantharidin treatment to prevent the development of secondary spinal injury in mice through the inhibition of cell apoptosis via a mitochondrial pathway.

CONCLUSION

Cantharidin treatment inhibits secondary injury in the spinal cord by suppressing caspase expression, which can occur via a mitochondria dependent apoptotic pathway. Therefore, cantharidin can be used for the treatment of secondary SCI.

REFERENCES

- Schmitt C, Miranpuri GS, Dhodda VK, Isaacson J, Vemuganti R, Resnick DK. Changes in spinal cord injury-induced gene expression in rat are straindependent. Spine J 2006; 6: 113-119.
- 2. Hong Z, Chen H, Hong H, Lin L, Wang Z. TSP-1 expression changes in diabetic rats with spinal cord injury. Neurol Res 2009; 31: 878-882.
- 3. Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, lacopino DG. Neuroprotection by erythropoietin 8. administration after experimental traumatic brain injury. Brain Res 2007; 1182: 99-105.
- 4. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic

- exploitation in brain disease. J Neurosurg Anesthesiol 2006; 18: 132-138.
- Lou J, Lenke LG, Ludwig FJ, O'Brien MF. Apoptosis as a mechanism of neuronal cell death following acute experimental spinal cord injury. Spinal Cord 1998; 6: 683-690.
- Curry SC, Carlton MW, Raschke RA. Prevention of fetal and maternal cyanide toxicity from nitroprusside with coinfusion of sodium thiosulfate in gravid ewes. Anesth Analg 1997; 84: 1121-1126.
- Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2a. FEBS Lett 1993; 330: 283-286.
- 8. Clarke PR, Hoffmann I, Draetta G, Karsenti E. Dephosphorylation of cdc25-C by a type-2A protein phosphatase: Specific regulation during the cell cycle in Xenopus egg extracts. Mol Biol Cell 1993; 4: 397-411.
- Chen YN, Chen JC, Yin SC. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002; 100: 158-165.
- Kok SH, Cheng SJ, Hong CY. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 2005; 217: 43-52.
- 11. Huan SK, Lee HH, Liu DZ, Wu CC, Wang CC. Cantharidin induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line. Toxicology 2006; 223: 136-143.
- 12. Williams LA, Moller W, Merisor E, Kraus W, Rosner H. In vitro anti-proliferation/cytotoxic activity of cantharidin (Spanish fly) and related derivatives. West Indian Med J 2003; 52: 10-13.
- 13. Yi SN, Wass J, Vincent P, Iland H. Inhibitory effect of norcantharidin on K562 human myeloid leukaemia cells in vitro. Leuk Res 1991; 15: 883-886.
- Chien SY, Wu YC, Chung JG, Yang JS, Lu HF, Tsou MF, Wood WG, Kuo SJ, Chen DR. Quercetin-induced apoptosis acts through mitochondrial- and caspase-3dependent pathways in human breast cancer MDA-MB-231 cells. Hum Exp Toxicol 2009; 28: 493-503.
- 15. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007; 13: 353-361.
- 16. Li W, Xie L, Chen Z. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci2015.
- Hsu SC, Yang JS, Kuo CL. Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line. J Orthop Res 2009; 27: 1637-1644.

Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson D, Briand C., Grutter MG. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002; 277: 45162-45171.